Oligometastatic Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Therapies, Companies by DelveInsight

Oligometastatic Disease Treatment Market

(Albany, USA) DelveInsight’s “Oligometastatic Disease Market Insights, Epidemiology, and Market Forecast 2034” report offers a detailed examination of Oligometastatic Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Oligometastatic Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here: Oligometastatic Disease Market Report

Key Findings from the Oligometastatic Disease Market Report:

• The Oligometastatic Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In September, 2024: Peter MacCallum Cancer Centre announced that the aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
• In August, 2024: Novartis Pharmaceuticals announced that the purpose of their study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor.
• In July, 2024: ImmuneSensor Therapeutics Inc. announced that a Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with NSCLC or RCC
• In May, 2024: Telix Pharmaceuticals (Innovations) Pty Limited announced that a phase II trial will evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer. TLX591 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radioisotope for the treatment of PSMA-expressing tumors.
• In 2023, the United States accounted for the highest number of oligometastatic disease cases with approximately 40% cases found in the 7MM.
• There were around 30,000 cases of oligorecurrent cases in the United States in 2023 and the highest number of oligorecurrent cases were observed in non-small cell lung cancer.
• According to DelveInsight’s patient-based forecasting model, the market size for oligometastatic disease in the 7MM was around USD 1,900 million in 2023, which is expected to significantly increase over the forecast period (2024-0234), owing to an increase in the cases and the launch of new therapies.
• Key Oligometastatic Disease Companies are as follows: ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company
• Key Oligometastatic Disease Therapies are as follow: AAA617, PNT2002 (177Lu-PNT2002), IMSA101
• Launching multiple stage Oligometastatic Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Oligometastatic Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ Oligometastatic Disease Treatment Market

Oligometastatic Disease Overview:

Oligometastatic disease refers to an intermediate stage of cancer progression, characterized by the presence of a limited number of metastatic lesions, typically fewer than five, confined to one or two distant sites. It is considered a distinct condition that lies between localized disease and widespread metastasis. Unlike advanced metastatic disease, where cancer has spread extensively, oligometastatic disease presents a more manageable scenario where localized treatments such as surgery, radiation therapy, or ablation can potentially achieve long-term control or even a cure.

Oligometastatic Disease Pipeline Development Activities:

Novel Immunotherapies: Investigational treatments that harness the body’s immune system are showing potential in early trials, aiming to enhance efficacy in oligometastatic settings.

Stereotactic Body Radiation Therapy (SBRT) with immunotherapy or targeted agents, which has shown encouraging preliminary results in improving progression-free survival.

Several investigational therapies have received fast track designations or breakthrough therapy statuses from regulatory agencies, reflecting their potential to address unmet medical needs in oligometastatic cancer treatment.

Oligometastatic Disease Market Insights:

Oligometastatic status has an increasing significance in the selection in appropriate treatment strategies available for metastatic disease. The primary goal of such treatment for patients with oligometastases is to prolong survival and the duration of cancer control.

• Surgical Treatment
• Radiotherapy
• Systemic therapy
• Combination Approaches

Oligometastatic Disease Drugs Uptake:

The uptake of targeted therapies, such as abiraterone and enzalutamide, is on the rise among patients with oligometastatic prostate cancer. Recent data indicate an increase in prescriptions over the past year, reflecting their effectiveness in prolonging survival.

Stereotactic Body Radiation Therapy (SBRT) is gaining popularity as a key treatment modality for oligometastatic patients. Recent studies highlight a significant rise in the number of patients receiving SBRT, attributed to its precision and ability to target limited metastases effectively.

The increasing recognition of the benefits of multidisciplinary care is driving higher uptake of combined treatment strategies. Patients are now more frequently receiving integrated regimens that combine surgery, systemic therapies, and radiation.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/oligometastatic-disease-market

Oligometastatic Disease Therapies and Key Companies:

• IMSA101: ImmuneSensor Therapeutics
• PNT2002 (177Lu-PNT2002): POINT Biopharma/Eli Lilly and Company
• AAA617: Novartis Pharmaceuticals
• And others

Oligometastatic Disease Epidemiology:

The dynamics of the Oligometastatic Disease market is anticipated to change in the coming years owing to the emerging pipeline and the rise in number of healthcare spending with the rise of awareness across the world. Key players, such as VectivBio, Hanmi Pharmaceutical, Zealand Pharma, etc. are involved in developing drugs for SBS-IF.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ Oligometastatic Disease Prevalence

Oligometastatic Disease Epidemiology Segmentation:

The Oligometastatic Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Incident Cases of Selected Tumor Type in the 7MM
• Total Oligometastatic Disease Incident Cases in the 7MM
• Total Oligometastatic Disease Diagnosed cases in the 7MM
• Total Treated cases of Oligometastatic Disease in the 7MM

Oligometastatic Disease Market Drivers:

• Increasing Awareness and Early Diagnosis
• Rising Incidence of Cancer
• Advancements in Targeted and Localized Therapies
• Growing Interest in Personalized Medicine

Oligometastatic Disease Market Barriers:

• Lack of Clear Treatment Guidelines
• High Cost of Advanced Treatments
• Limited Awareness in Developing Regions
• Complexity of Patient Selection

Scope of the Oligometastatic Disease Market Report:

• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Oligometastatic Disease Companies: ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company
• Key Oligometastatic Disease Therapies: AAA617, PNT2002 (177Lu-PNT2002), IMSA101
• Oligometastatic Disease Therapeutic Assessment: Current marketed and emerging therapies
• Oligometastatic Disease Market Dynamics: Oligometastatic Disease Market drivers and Oligometastatic Disease barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Oligometastatic Disease Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Oligometastatic Disease market outlook, drug uptake, treatment scenario, and epidemiology trends: Oligometastatic Disease Clinical Trials and Updates

Table of Content:

1. Key Insights

2. Report Introduction

3. Oligometastatic Disease Market Overview at a Glance

4. Executive Summary of Oligometastatic Disease

5. Disease Background and Overview

6. Methodology

7. Epidemiology and Patient Population

8. Patient Journey

9. Emerging Therapies

10. Oligometastatic Disease: Seven Major Market Analysis

11. KOL Views

12. SWOT Analysis

13. Unmet Needs

14. Market Access and Reimbursement

15. Appendix

16. DelveInsight Capabilities

17. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting